Crinetics Pharmaceuticals (CRNX) Accumulated Expenses (2017 - 2026)

Crinetics Pharmaceuticals' Accumulated Expenses history runs 10 years deep, the most recent figure standing at $25.8 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 55.32% year-over-year to $25.8 million; the TTM figure through Mar 2026 stood at $25.8 million (up 55.32% YoY), while the FY2025 annual figure was $35.6 million, up 23.16% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $25.8 million, down from $35.6 million in the prior quarter.
• The five-year high for Accumulated Expenses was $35.6 million in Q4 2025, with the low at $4.5 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $14.8 million (2024), against an average of $17.2 million.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses jumped 137.03% in 2024, then rose 6.97% in 2025.
• Crinetics Pharmaceuticals' Accumulated Expenses stood at $9.1 million in 2022, then soared by 59.86% to $14.5 million in 2023, then soared by 98.99% to $28.9 million in 2024, then increased by 23.16% to $35.6 million in 2025, then retreated by 27.51% to $25.8 million in 2026.
• Business Quant data shows CRNX's Accumulated Expenses at $25.8 million in Q1 2026, $35.6 million in Q4 2025, and $32.4 million in Q3 2025.